Ekso Bionics Holdings, Inc. Q2 FY2025 Earnings Call

· Earnings call transcript and AI-powered summary

Quarter Overview

  • Q2 2025 revenue was approximately $2.1M, a significant decline from $5.0M in Q2 2024. Management attributed this primarily to short-term delays in completing two multi-unit Enterprise Health sales.
  • Gross profit was around $0.8M, down from $2.6M in Q2 2024. Gross margin declined to 40% from 53% year-over-year, mainly due to decreased Enterprise Health sales and higher shipping costs, partly offset by improved service margins.
  • Operating expenses totaled $4.8M, a slight improvement compared to $5.0M in Q2 2024.
  • Net loss increased to $2.7M versus $2.4M in Q2 2024; however, loss per share improved due to a larger share count ($1.24 vs. $1.99).
  • Cash and restricted cash at quarter-end was $5.2M.

Business Performance & Market Dynamics

  • Management emphasized that Q2 weakness was abnormal and primarily due to deferred Enterprise Health deals rather than underlying demand deterioration.
  • Two delayed multi-unit Enterprise Health sales totaled roughly $1.4M:
    • An international order delayed by regulatory issues (expected in 2025).
    • A North American integrated delivery network (IDN) order of around $1M, expected to close in Q3 2025.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Greetings, and welcome to the Ekso Bionics Second Quarter 2025 Financial Results Conference Call. [Operator Instructions]. It is now my pleasure to introduce your host, Stephen Kilmer, Investor Relations. Thank you. You may begin. Stephen Kilmer: Thank you, operator, and good afternoon, everyone. Earlier today, Ekso Bionics released financial results for the second quarter ended June 30, 2025. A copy of the press release is available on our website. I would like to point out that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be deemed to be forward- looking statements. All forward-looking statements, including statements regarding our business strategy, future financial or operational expectations, our ability to close on delayed customer sales, our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward- looking statements. Accordingly, you should not place undue reliance on these statements. For a list and descripti

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional